
A recent report urging people using GLP-1 medications not to overlook movement and mental-health is reinforced by new evidence that these drugs can alter brain function. The possibility that GLP-1s may lower breast cancer risk adds another potential benefit to consider alongside exercise and mental‑health support, but it does not reduce the need for clinicians to monitor mood, cognition and physical activity. Patients and providers should continue routine mental-health screening and individualized movement planning while watching for emerging long-term data on other health outcomes.
Click a connection line between nodes to view confidence and evidence.